Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q3

2784.TEDINET S100SVSS
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥2.18T2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥2.70T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥2.05T2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥29.9bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥20.0bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥31.2bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥32.8bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥22.0bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥30.9bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥22.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥20.9bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥25.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥14.8bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥20.9bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥14.9bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥1.50Tat 2023-12-31Cons.Assets
Total assets¥1.34Tat 2023-03-31Cons.Assets
Total assets¥1.44Tat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥1.04Tat 2023-12-31Cons.Liabilities
Total liabilities¥851.5bnat 2023-03-31Cons.Liabilities
Net assets / equity¥464.3bnat 2023-12-31Cons.Net assets
Net assets / equity¥488.3bnat 2023-03-31Cons.Net assets
Net assets / equity¥481.9bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥200.8bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥160.1bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥107.922023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥48.222023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥127.422022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥73.242022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.642022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.9%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 45
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥26.2bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥26.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31¥290m
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥1.94T
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥1.92T
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥14.0bn
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥25.9bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥40.0bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥28.2bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥11.7bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥1.1bn
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥27.5bn
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥27.5bn
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥484m
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥200.4bn
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥200.0bn
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥395m
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥2.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥2.21T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥2.18T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥26.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥29.7bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥24.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥24.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥372m
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.82T
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.81T
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥16.9bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥36.4bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥25.8bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10.6bn
jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥992m
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥27.1bn
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥27.1bn
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥43m
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥186.8bn
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥186.3bn
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥429m
jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥2.07T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥2.05T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥24.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥19.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 381
ItemContextValueUnit
Notes and accounts payable tradeCurrentQuarterInstant936005000000JPY
Income taxes payablePrior1YearInstant6046000000JPY
Income taxes payableCurrentQuarterInstant1676000000JPY
Provision for bonusesPrior1YearInstant7210000000JPY
Provision for bonusesCurrentQuarterInstant3510000000JPY
Provision for directors bonusesPrior1YearInstant384000000JPY
Provision for directors bonusesCurrentQuarterInstant290000000JPY
Provision for loss on anti monopoly act clPrior1YearInstant4937000000JPY
Provision for loss on anti monopoly act clCurrentQuarterInstant4937000000JPY
Other clPrior1YearInstant26810000000JPY
Other clCurrentQuarterInstant30525000000JPY
Current liabilitiesPrior1YearInstant825732000000JPY
Current liabilitiesCurrentQuarterInstant976945000000JPY
Bonds payablePrior1YearInstant－JPY
Bonds payableCurrentQuarterInstant20000000000JPY
Long term loans payablePrior1YearInstant－JPY
Long term loans payableCurrentQuarterInstant10000000000JPY
Provision for share based remuneration nclPrior1YearInstant73000000JPY
Provision for share based remuneration nclCurrentQuarterInstant148000000JPY
Provision for share based remuneration for directors and other officers nclPrior1YearInstant90000000JPY
Provision for share based remuneration for directors and other officers nclCurrentQuarterInstant201000000JPY
Net defined benefit liabilityPrior1YearInstant8363000000JPY
Net defined benefit liabilityCurrentQuarterInstant7735000000JPY
Other nclPrior1YearInstant17257000000JPY
Other nclCurrentQuarterInstant20740000000JPY
Noncurrent liabilitiesPrior1YearInstant25784000000JPY
Noncurrent liabilitiesCurrentQuarterInstant58825000000JPY
LiabilitiesPrior1YearInstant851517000000JPY
LiabilitiesCurrentQuarterInstant1035771000000JPY
Capital stockPrior1YearInstant18454000000JPY
Capital stockCurrentQuarterInstant18454000000JPY
Capital surplusPrior1YearInstant57720000000JPY
Capital surplusCurrentQuarterInstant57720000000JPY
Retained earningsPrior1YearInstant366649000000JPY
Retained earningsCurrentQuarterInstant375820000000JPY
Treasury stockPrior1YearInstant-686000000JPY
Treasury stockCurrentQuarterInstant-36410000000JPY
Shareholders equityPrior1YearInstant442137000000JPY
Shareholders equityCurrentQuarterInstant415583000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant47135000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant49871000000JPY
Deferred gains or losses on hedgesPrior1YearInstant-0JPY
Deferred gains or losses on hedgesCurrentQuarterInstant-2000000JPY
Revaluation reserve for landPrior1YearInstant-3346000000JPY
Revaluation reserve for landCurrentQuarterInstant-3375000000JPY
Foreign currency translation adjustmentPrior1YearInstant269000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant385000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1895000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant1577000000JPY
Valuation and translation adjustmentsPrior1YearInstant45953000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass